What's in Md Mehedi Shahriar's pipeline?

Md Mehedi Shahriar has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Md Mehedi Shahriar's portfolio?

Top competitors by shared drug class: EA Pharma Co., Ltd., Ironwood Pharmaceuticals, Inc..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/md-mehedi-shahriar.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Md Mehedi Shahriar — Portfolio Competitive Intelligence Brief

Md Mehedi Shahriar pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Linaclotide 145 micrograms	Linaclotide 145 micrograms	marketed
Linaclotide 72 micrograms	Linaclotide 72 micrograms	marketed	Guanylate cyclase-C agonist	GC-C (guanylate cyclase-C receptor)	Gastroenterology

Therapeutic area mix

Gastroenterology · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

EA Pharma Co., Ltd. · 1 shared drug class
Ironwood Pharmaceuticals, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Md Mehedi Shahriar:

Cite this brief

Drug Landscape (2026). Md Mehedi Shahriar — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/md-mehedi-shahriar. Accessed 2026-05-16.